FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
Schizophrenia affects how a person thinks ... clinical associate professor of pharmacotherapy and translational sciences at ...
Medpage Today on MSN15d
Magnetic Stimulation Reduced Auditory Hallucinations in Patients With Schizophrenia
For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...
Cambridge University Press1y
Essential Evidence-Based Psychopharmacology
Vaughan, John S. March and Christopher J. Kratochvil 2. Evidence-based pharmacotherapy of schizophrenia Stefan Leucht, Stephan Heres, Werner Kissling and John M. Davis 3. Evidence-based ...
Nature5y
Tuning muscarinic receptor signalling
The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...
Medscape3d
Hallucinations in Acutely Admitted Patients With Psychosis, and Effectiveness of Risperidone, Olanzapine, Quetiapine, and Ziprasidone
Background: Hallucinations are prevalent in schizophrenia and related psychotic ... this could pave the way for a more targeted pharmacotherapy based on individual symptom profiles, rather than ...
Nature3mon
Psychiatric drug discovery on the couch
For example, antidepressant pharmacotherapy is still dominated by neurotransmitter reuptake inhibitors. Similarly, for schizophrenia, the first-line therapies are atypical antipsychotics ...
Forbes21d
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action ...